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Abstract
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been recently reported as a new
approach for intraperitoneal chemotherapy (IPC). By means of a patented micropump, the liquid chemotherapy is
delivered into the peritoneal cavity as an aerosol which is supposed to achieve “gas-like” distribution. However,
recent data report that the fraction of the submicron aerosol (gas-like) is less than 3 vol% of the total amount of
aerosolized chemotherapy. Until today, possible modifications of treatment parameters during PIPAC with the aim
of improving therapeutic outcomes have not been studied yet.
This study aims to establish an in vitro PIPAC model to explore the cytotoxic effect of the submicron aerosol
fraction and to investigate the impact of different application parameters on the cytotoxic effect of PIPAC on
human colonic cancer cells.
Methods: An in vitro model using HCT8 colon adenocarcinoma wild-type cells (HCT8WT) and multi-chemotherapy
refractory subline (HCT8RT) was established. Different experimental parameters such as pressure, drug dosage, time
exposure, and system temperature were monitored in order to search for the conditions with a higher impact on
cell toxicity. Cell proliferation was determined by means of colorimetric MTT assay 48 h following PIPAC exposures.
Results: Standard operational parameters applied for PIPAC therapy depicted a cytotoxic effect of the submicron
aerosol fraction generated by the PIPAC micropump. We also observed that increasing pressure significantly
enhanced tumor cell toxicity in both wild-type and chemotherapy-resistant cells. A maximum of cytotoxicity was
observed at 15 mmHg. Pressure >15 mmHg did not show additional cytotoxic effect on cells. Increased oxaliplatin
dosage resulted in progressively higher cell toxicity as expected. However, in resistant cells, a significant effect was
only found at higher drug concentrations. Neither an extension of exposure time nor an increase in temperature of
the aerosolized chemotherapy solution added an improvement in cytotoxicity.
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Conclusions: In this in vitro PIPAC model, the gas-like PIPAC aerosol fraction showed a cytotoxic effect which was
enhanced by higher intra-abdominal pressure with a maximum at 15 mmHg. Similar findings were observed for
drug dose escalation. A phase I dose escalation study is currently performed at our institution. However, increasing
the intra-abdominal pressure might be a first and simple way to enhance the cytotoxic effect of PIPAC therapy
which needs further clinical investigations.
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Background
The survival benefit of intraperitoneal chemotherapy
(IPC) was first demonstrated more than 20 years ago
and has since then been confirmed in multiple additional
trials. However, inadequate drug delivery to solid tumors
is a major reason for treatment failure in systemic and
IPC strategies [1, 2]. One of the assumed reasons is an
increased intratumoral pressure hampering the convective
influx of anticancer drugs into the tumoral tissue as
opposed to normal tissue [3].
Pressurized intraperitoneal aerosol chemotherapy
(PIPAC) has been recently reported as a new ap-
proach for IPC which could overcome the outlined
limitations of IPC with liquid solutions. Using a
micropump, the drug containing solution is delivered
into the abdominal cavity in the shape of micro
droplets within the 12 mmHg capnoperitoneum.
Semi-quantitative in vivo animal experiments report
uniform drug distribution in the abdominal cavity
since the aerosol droplets are assumed to behave
“gas-like” [4]. Furthermore, the increased intra-
abdominal pressure in the shape of a capnoperito-
neum of 12 mmHg C02 counteracts the increased
intratumoral pressure which amplifies the influx of
drugs into the tumor tissue. Penetration depth into
tumoral tissue is reported to be as deep as 500 to
600 μm with high tissue concentrations observed up
to 1.70 μmol/g [5]—which is assumed to be higher
than observed for liquid IPC. Yet, so far, PIPAC has
never been compared to any liquid IPC treatment in
a preclinical or clinical setting.
Recently published data report that the spatial drug
distribution pattern of PIPAC is non-homogeneous.
Furthermore, the aerosol delivered by the PIPAC micro-
pump has a mean droplet size which is too large to
distribute homogeneously. About 97.5 vol% of the deliv-
ered aerosol droplets are not submicronic and have not
the physical properties to distribute gas-like [6]. Tissue
areas located outside the aerosol spray jet of the PIPAC
micropump only show a minimal drug exposure to the
submicronic PIPAC aerosol [7].
In the clinical setting, a recently published phase II
trial with doxorubicin and cisplatin in women suffering
from recurrent platinum-resistant ovarian cancer delivered
into the abdominal cavity as a pressurized aerosol endorsed
the preclinical findings with a reported clinical benefit
rate of 68% and a low incidence of severe side effects
[8]. Similar findings are reported in patients suffering
from platinum-resistant peritoneal carcinomatosis from
colorectal cancer (pcCRC) treated with PIPAC and oxa-
liplatin in a compassionate use program for patients
who did not qualify for cytoreductive surgery (CRS)
and heated intraperitoneal chemotherapy (HIPEC) [9].
While first clinical results are encouraging, there re-
main a number of patients who show no response to
PIPAC therapy or suffer an early disease relapse follow-
ing an initial tumor regression after PIPAC therapy. In a
clinical setting, it would crucial if one could increase the
cytotoxic effect of PIPAC therapy by modulating differ-
ent treatment parameters. However, the treatment pa-
rameters currently in use, i.e., intra-abdominal pressure,
exposure time of the peritoneum to the pressurized
aerosol, and temperature and dosage/concentration of
the drugs delivered, have never been explored in detail
and are solely based on assumptions and data derived
from liquid IPC. Based on the above background data,
we aimed to establish an in vitro PIPAC model to investi-
gate any cytotoxic effect of the submicronic PIPAC
aerosol and to explore a possible effect of different
treatment parameters to modulate cytotoxicity.
Due to its technical design, the currently used PIPAC
technology cannot be utilized in a small animal model of
peritoneal carcinomatosis while a large animal model with
a body size equivalent to the human body has never been
established. Therefore, based on a previously established
in vitro PIPAC model, colonic cancer cells were directly
exposed to the PIPAC test atmosphere, a common model
to assess cytotoxicity in aerosol science.
Methods
Cell cultures
The human colorectal cancer cell lines HCT8 were
obtained from the Cell & Tumor Bank of the University
Duisburg-Essen, Medical School. The HCT8 cell line is
well characterized and frequently used in preclinical investi-
gations since its resistant entity reveals highly metastatic
rates in animal models, which mimic very well the clinical
situation seen in peritoneal carcinomatosis [10–12].
Khosrawipour et al. World Journal of Surgical Oncology  (2017) 15:43 Page 2 of 7
Previous studies conducted in 3D cultures revealed no dif-
ferences respecting 2D cultures. Chemoresistance was
induced with etoposide which is very particular since it in-
duces a cross-resistance behavior against several cytostatic
drugs, including cisplatin and its derivatives (see Additional
file 1). Both wild type (wt) and chemotherapy resistant type
(rt) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; PAN-BIOTech., No. P04-04510, PAN
Biotech GmbH, Aidenbach, Germany), supplemented with
10% heat-inactivated fetal bovine serum, also purchased
from PAN Biotech GmbH, 0.8 μl/ml of doxycycline, and in-
cubated at 37 °C in a humidified 5% CO2/air atmosphere.
Cells were seeded in 24-well plates at a density of 20,000
cells of HCT8 and 40,000 cells of HCT8RETO (colon adeno-
carcinoma cell line resistant to etoposide) per well and in-
cubated at 37 °C with 5% CO2. During the PIPAC
experiments, the cell cultures medium was aspired, so that
the cells were directly exposed to the test atmosphere. After
the exposure period, the cell cultures were immediately
covered with medium and the culture was continued for
48 hrs. At the end of the treatment 200 μl of MTT solu-
tion (5 mg/ml in PBS) were added into each well, followed
by incubation at 37 °C for 3 h. The culture medium con-
taining MTT was aspirated, and the formazan crystals
formed were then solubilized with 200 μl DMSO for
30 min. Absorbance was measured at wave length 570 nm
in a microplate reader (Tecan, Basel, Switzerland), and the
percentage of proliferation was determined for all groups.
Ex vivo PIPAC model and PIPAC procedures
The ex vivo PIPAC model has been previously described
in detail [7]. In brief, the PIPAC model was placed in a
water bath and kept at a constant temperature of 37 °C
during the entire procedure. For each experiment, two 24-
well plates (TPP techno Plastic Products AG, Trasadingen,
Switzerland) were then placed at the bottom of the plastic
box, laterally of the aerosol jet spray, and covered with a
bilaterally open plastic tunnel to avoid direct exposure of
the tumor cells to the aerosol jet of the MIP® (MIP®,
Reger Medizintechnik, Rottweil, Germany). The plas-
tic box was then tightly sealed, and the CO2 capno-
peritoneum (Olympus UHI-3; Olympus, medical life
science and industrial divisions, Olympus Australia,
Notting Hill, Australia) was established and continued
for the entire PIPAC procedure. Oxaliplatin (Teva
GmbH, Radebeul, Germany) was first aerosolized
(aerosol phase) and then applied onto the exposed
tumor cells (exposure phase).
The clinical standard of PIPAC therapy for pcCRC is
as follows: oxaliplatin (92 mg/m2 body surface at 23 °C)
diluted in 150 ml glucose 5% is aerosolized in a capno-
peritoneum of 12 mmHg at 36 °C [9]. The drug solution
is delivered with a flow of 30 ml/min (Injektron 82 M,
MedTron, Saarbrücken, Germany) to a patented
micropump which delivers a polydisperse aerosol. After
termination of the injection of the chemotherapy solu-
tion (aerosol phase), the peritoneal cavity is exposed for
another 30 min (exposure phase) to the oxaliplatin aero-
sol. To investigate the role of the different treatment
parameters on tumor cell cytotoxicity, the experiments
were performed as follows.
Cell culture exposure to test aerosol atmosphere
To test any cytotoxic effect of the PIPAC test atmos-
phere on medium free cell cultures, the cell cultures
were exposed to an aerosol phase of 5 min with 150 ml
glucose 5%, capnoperitoneum of 12 mmHg, 36 °C, and
variable exposure phase of 0, 15, 30, and 45 min. Control
group (CG): 150 ml glucose 5% but cell cultures exposed
to PIPAC aerosol in medium.
Oxaliplatin dose
Aerosol phase of 5 min, exposure time of 30 min, and
a constant capnoperitoneum of 12 mmHg at 36 °C.
Oxaliplatin doses of 92, 138, and 184 mg diluted in
150 ml glucose 5% at 23 °C. CG: 150 ml glucose 5%.
Pressure
Aerosol phase 5 and 30-min exposure time with oxali-
platin (92 mg in 150 ml glucose 5% at 23 °C). Variable
pressure of the capnoperitoneum: 5, 10, 15, and
20 mmHg at 36 °C. CG: PIPAC at atmospheric pressure.
Exposure time
Oxaliplatin (92 mg in 150 ml glucose 5%) at 23 °C and
aerosol phase of 5 min in a constant capnoperitoneum
of 12 mmHg at 36 °C. Variable exposure time: 15, 30,
and 45 min, respectively. CG: no aerosol exposure time.
Temperature of the oxaliplatin solution
Oxaliplatin (92 mg in 150 ml glucose 5%) and aerosol
phase and exposure time of 5 and 30 min with a
12 mmHg capnoperitoneum at 36 °C. Temperature of
the oxaliplatin solution aerosolized: 27, 36, and 43 °C.
CG: oxaliplatin delivered at 23 °C.
Statistical analysis
All experiments were performed at least in triplicate. Each
well was considered as a single value, corresponding to
the subgroups. The Kruskal-Wallis one-way analysis of
variance on ranks was used to compare independent
groups. Probability (p) values were considered as follows:
*p < 0.05; **p < 0.01; ***p < 0.001; #p > 0.05.
Results
Cell culture exposure to test atmosphere
The cell viability in the cell cultures directly exposed to
the test PIPAC atmosphere (no medium) was similar to
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that observed for those covered with medium (sub-
merged exposure). During the aerosol and exposure
phase, the humidity in the PIPAC model remained at
100% with a constant temperature between 36 and 37 °C
(data not shown).
Oxaliplatin dose escalation
Compared to the CG, significantly higher cell toxicity
was observed in all treatment groups (rt and wt cells;
p < 0.001). In wt cells, any increase of oxaliplatin
dosage progressively leads to significantly higher cell
cytotoxic (p < 0.05).
However, this effect was not observed in rt cells
comparing 92 vs. 138 mg (p > 0.05). Nevertheless, an
increase from 138 to 184 mg resulted in higher tumor
cell death (138 vs. 184 mg; p < 0.001). The results of
dose escalation are summarized in Fig. 1.
Effect of pressure
Increase of pressure significantly affects cytotoxicity.
A maximum was observed at a pressure of 15 mmHg
since a further increase of pressure to 20 mmHg did
not result in significantly higher cell toxicity (15 vs.
20 mmHg; p > 0.05). The effect of pressure is
summarized in Fig. 2.
Exposure time and temperature of the oxaliplatin solution
Standard PIPAC without additional exposure time
served as CG. Additional exposure time of 15, 30, and
45 min did not affect the cytotoxic effect. The same
observation was made with an increase of temperature
of the oxaliplatin solution (27, 36, and 43 °C; data not
shown).
Discussion
One of the key elements of PIPAC therapy is the fact
that the intra-abdominal drug distribution pattern is
homogeneous since the aerosol would behave gas-like.
However, this is in strong contrast to recent findings
which report that the aerosol fraction which can dis-
tribute gas-like (submicron aerosol) is less than 3 vol%
of the total amount of the chemotherapy delivered dur-
ing PIPAC therapy [6]. This observation is in strong
contrast to first clinical data about PIPAC therapy
where up to 70% of patients suffering from chemoresis-
tant end-stage peritoneal carcinomatosis show objective
regression of PC. In our current in vitro PIPAC model,
the submicron (gas-like) test aerosol showed cell cyto-
toxicity. This fact is even more important, since PIPAC
therapy for colorectal peritoneal carcinomatosis uses
only 20% of liquid IPC. Taken together, 3 vol% of sub-
micron PIPAC aerosol out of only 20% of a liquid IPC
dose induces cytotoxicity in multi-chemoresistant co-
lonic cancer cells in our in vitro model. These findings
have important implementations. First, our data are an
additional argument to support the PIPAC concept.
Second, if technical innovations can furthermore in-
crease the fraction of submicron aerosol delivered dur-
ing PIPAC therapy, the efficiency of this approach
could probably be further increased.
Fig. 1 Effect of oxaliplatin dose escalation on cell toxicity. Control control group; 100% = 92 mg; 150% = 138 mg; 200% = 184 mg
oxaliplatin. *p < 0.05; **p < 0.01; ***p < 0.001; #p > 0.05
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In contrast to lung medicine and inhalation toxicology,
there are so far no standardized models which would
allow easy and reliable testing of different chemotherapy
aerosol to treat peritoneal carcinomatosis. Our presented
PIPAC model is a simple and easy testing tool which is
based on the principle of air-liquid interface testing
systems, where the cells are grown on a permeable
membrane in contact with an underlying medium and
the cells are directly exposed to a constant test atmos-
phere. However, the constant flow of the test atmosphere
induces dry out effects of the cells and changes in the
environmental cell milieu. In contrast to this, the PIPAC
aerosol is delivered in a constant capnoperitoneum with
no flow effects and a constant temperature and humidity
of 100%. With that background, we exposed the cell cul-
tures without any medium and observed that the cell via-
bility after an exposure time of up to 50 min to a test
atmosphere of glucose 5% remained intact. Therefore, we
believe that our in vitro PIPAC aerosol exposure
model is a first step to assess the toxic effect of
different aerosols applied for possible PIPAC therapy
without the disadvantages for cell cultures under
submerged conditions.
Since the first clinical use of PIPAC, the possibility to
further enhance the antitumor effect by an additional
increase of the intra-abdominal pressure (IAP) >12 mmHg
has never been investigated. Our current study shows that
a progressive increase of the IAP results in significantly
higher rates of tumor cell death in both wild and
chemoresistant tumor cells. A further increase of IAP to
20 mmHg showed an additional yet not significant cyto-
toxic effect compared to 15 mmHg. However, we are
aware of the fact that our in vitro cell experiments have
some limitations and must be interpreted with caution
with respect to in vivo pharmacokinetics. Nevertheless,
our findings are in line with previous results obtained in
animal models. Jacquet at al. have proposed to increase
the IAP to counteract the elevated intra-tumoral pressure
for improving the tissue penetration depth and tissue con-
centrations of doxorubicin for IPC. A significantly in-
creased tissue concentration of doxorubicin at an IAP of
20 to 30 mmHg could be observed in a rat model [13].
Esquis and co-workers demonstrated in a rodent periton-
eal carcinomatosis model that increased IAP of 22 mmHg
for 1 h resulted in a significantly higher cisplatin penetra-
tion in tumoral tissue and improved survival of the ani-
mals [14] and even a moderate increase of IAP
(18 mmHg) in healthy pigs showed significantly increased
tissue concentrations for cisplatin [15, 16]. However, the
cutoff range of increased IAP where pharmacological
characteristics of IPC are optimized but with an accept-
able additional risk of local and systemic complications
due to the increased IAP is not known. Nevertheless, in
clinical use, safe laparoscopic HIPEC procedures with an
IAP up to 15 mmHg for palliating malignant ascites have
been reported [17], and a capnoperitoneum of 20 mmHg
can be safely performed in most cases [18]. Therefore, an
increase of the IAP >15 mmHg may be a valuable option
in patients who show no response to repetitive standard
PIPAC therapy or suffer from a disease relapse shortly
after successful PIPAC therapy. However, the established
occupational health safety concept of PIPAC therapy has
only been explored for an IAP of 12 mmHg [19].
In most centers, CRS and HIPEC for pcCRC are
currently performed with oxaliplatin. Oxaliplatin dosage
for PIPAC therapy in patients who do not qualify for CRS
and HIPEC is currently 92 mg/m2 body surface diluted in
150 ml of glucose 5% [16]. Until today, a higher drug
Fig. 2 Effect of pressure on tumor cell cytotoxicity: 0 mmHg = control group; *p < 0.05; **p < 0.01; ***p < 0.001; #p > 0.05
Khosrawipour et al. World Journal of Surgical Oncology  (2017) 15:43 Page 5 of 7
dosage for PIPAC therapy has not been investigated. Our
first in vitro data on dose escalation found a significantly
higher cytotoxic effect of PIPAC therapy in wild-type co-
lonic cancer cells for 138 and 184 mg of delivered oxali-
platin. Increased drug dosage is assumed to amplify in
tissue depth penetration and in tissue drug concentra-
tions. Yet, a significantly increased cell death rate in
chemotherapy-resistant tumor cells was only attained
when the dose was doubled from 92 to 184 mg. With re-
gard to our data, we view a dose escalation as a valuable
tool in patients who show no response to standard PIPAC
therapy regiments. Currently, a phase I dose escalation
study for PIPAC with cisplatin and doxorubicin is running
at our institution [20]. However, for oxaliplatin, dose find-
ing studies are urgently needed.
To date, a wide variety in the duration (30 to 120 min)
of intraperitoneal chemotherapy protocols (HIPEC) has
been reported. In PIPAC therapy, the chemotherapy
drug is aerosolized during 5 min with an additional
exposure time of 30 min. In our current in vitro PIPAC
model, additional exposure time showed no increase in
the cytotoxic effect. Similar findings were reported by
Jacquet et al. in a rat model. IPC with an increased IAP
showed significantly higher tissue concentrations with
its maximum already after 10 min of exposure time [13].
Studies with growth inhibition assays on human lung
cancer cells show that dose escalation with increased
concentrations of gemcitabine delivered as an aerosol
enhanced the cytotoxic effect while prolonged exposure
time did not [21]. Since aerosol has an optimum of
surface area at the interface of the tumor, the influx of
antineoplastic drugs into peritoneal and tumoral tissue
seems to achieve high tissue drug concentrations already
after a short exposure time. Thus, in a clinical setting,
exposure time may be shortened resulting in reduced
intervention time as well as minimized operative trauma
to the patient while saving health care costs.
As the final parameter, a rise in drug temperature was
analyzed with regard to a possible enhanced cytotoxic
effect. Hyperthermia itself is known to induce cytotox-
icity of malignant cells, augment the cytotoxic effect of
different chemotherapeutic drugs such as doxorubicin
and platin compounds, and increase the penetration
depth of the chemotherapeutic drugs (reviewed in [22]).
During PIPAC therapy, the intra-abdominal temperature
cannot be increased since the abdominal cavity is a
closed system. Theoretically, a local hyperthermia could
be achieved by insufflation of heated C02 (41–43 °C)
prior to delivering PIPAC. However, during the procedure,
no heated C02 can be delivered anymore, and the
temperature would rapidly decrease to levels of body
temperature. Since data of aerosol therapy of the lung re-
ported that an increase of temperature of the aerosolized
liquid drug decreases the viscosity and surface tension
leading to a reduced aerosol droplet size and a higher sat-
urated vapor pressure [23]—thermodiffusion could add-
itionally improve the aerosol deposition on the tumoral
tissue and enhance drug influx. Based on these data, we
explored whether an increase of the temperature of the
aerosolized drug would be a possibly easy and cheap way
to enhance the effectiveness of PIPAC therapy. However,
our theoretical assumptions were not confirmed in our in
vitro PIPAC model. Even at a temperature of 43 °C of the
aerosolized chemotherapeutic liquids, no additional cyto-
toxic effect was explored. However, a recently published
research article reported about the safety and feasibility of
hyperthermic PIPAC (H-PAC) in an experimental setting
in a swine model [24].
The theoretical assumptions on a possible benefit of
hyperthermia were not confirmed in our in vitro PIPAC
model. Even at a temperature of 43 °C of the aerosolized
chemotherapeutic liquids showed no additional cytotoxic
effect.
Conclusions
Aware of the limitations of our in vitro experiments, we
aimed to give an insight on the cytotoxic effect of PIPAC
as well as have an outlook on how clinical parameters
may be modified in the near future. Increased IAP and
drug dose escalation amplify the cytotoxic effect, while
prolonged exposure time to the aerosol shows no amplifi-
cation. Our data are in line with previous reports from in
vivo animal and in vitro cell experiments. However, fur-
ther basic research is required to increase the evidence of
our findings.
When PIPAC therapy was first applied to patients, the
treatment parameters were mostly based on assumptions,
limited experimental data, and personal expertise. How-
ever, we believe that in patients who show no response to
standard PIPAC therapy or who show tumor regression
after successful PIPAC therapy, an increase of IAP to 15
to 20 mmHg as well as dose escalation might be a valuable
clinical option.
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